{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF00531",
      "entity_text" : "death",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01220",
      "entity_text" : "SUSTAIN-6",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The recently published LEADER and SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% and 24%, respectively.",
  "reading_complete" : "2020-07-28T13:15:48Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T13:12:11Z",
  "trigger" : "reduce",
  "evidence" : [ "SUSTAIN-6 trials demonstrate that, in T2D patients with high CVD risk, the glucagon-like peptide 1 receptor agonists liraglutide and semaglutide reduce the primary major adverse cardiac events (MACE) end point (cardiovascular death" ],
  "pmc_id" : "5481984",
  "score" : 0
}